Loading...
Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
Everolimus (RAD001) is an inhibitor of mammalian target of rapamycin used in combination with exemestane to treat hormone receptor-positive advanced breast cancer. However, not all patients are equally sensitive to RAD001 and certain patients develop resistance. Therefore, the present study analyzed...
Na minha lista:
| Udgivet i: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5587981/ https://ncbi.nlm.nih.gov/pubmed/28927154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6597 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|